These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 36710683)

  • 1. Evaluation of Blood-Based Plasma Biomarkers as Potential Markers of Amyloid Burden in Preclinical Alzheimer's Disease.
    Winston CN; Langford O; Levin N; Raman R; Yarasheski K; West T; Abdel-Latif S; Donohue M; Nakamura A; Toba K; Masters CL; Doecke J; Sperling RA; Aisen PS; Rissman RA
    J Alzheimers Dis; 2023; 92(1):95-107. PubMed ID: 36710683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining plasma Aβ and p-tau217 improves detection of brain amyloid in non-demented elderly.
    Niimi Y; Janelidze S; Sato K; Tomita N; Tsukamoto T; Kato T; Yoshiyama K; Kowa H; Iwata A; Ihara R; Suzuki K; Kasuga K; Ikeuchi T; Ishii K; Ito K; Nakamura A; Senda M; Day TA; Burnham SC; Iaccarino L; Pontecorvo MJ; Hansson O; Iwatsubo T
    Alzheimers Res Ther; 2024 May; 16(1):115. PubMed ID: 38778353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood Derived Amyloid Biomarkers for Alzheimer's Disease Prevention.
    Udeh-Momoh C; Zheng B; Sandebring-Matton A; Novak G; Kivipelto M; Jönsson L; Middleton L
    J Prev Alzheimers Dis; 2022; 9(1):12-21. PubMed ID: 35098969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis.
    West T; Kirmess KM; Meyer MR; Holubasch MS; Knapik SS; Hu Y; Contois JH; Jackson EN; Harpstrite SE; Bateman RJ; Holtzman DM; Verghese PB; Fogelman I; Braunstein JB; Yarasheski KE
    Mol Neurodegener; 2021 May; 16(1):30. PubMed ID: 33933117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma Aβ42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: a cross-sectional analysis from the AB255 Study.
    Pérez-Grijalba V; Arbizu J; Romero J; Prieto E; Pesini P; Sarasa L; Guillen F; Monleón I; San-José I; Martínez-Lage P; Munuera J; Hernández I; Buendía M; Sotolongo-Grau O; Alegret M; Ruiz A; Tárraga L; Boada M; Sarasa M;
    Alzheimers Res Ther; 2019 Dec; 11(1):96. PubMed ID: 31787105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alzheimer's cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans : CSF AD biomarkers measured by Lumipulse in Koreans.
    Moon S; Kim S; Mankhong S; Choi SH; Vandijck M; Kostanjevecki V; Jeong JH; Yoon SJ; Park KW; Kim EJ; Yoon B; Kim HJ; Jang JW; Hong JY; Park DH; Shaw LM; Kang JH
    Alzheimers Res Ther; 2021 Jan; 13(1):22. PubMed ID: 33436035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical performance of an antibody-free assay for plasma Aβ42/Aβ40 to detect early alterations of Alzheimer's disease in individuals with subjective cognitive decline.
    Pascual-Lucas M; Allué JA; Sarasa L; Fandos N; Castillo S; Terencio J; Sarasa M; Tartari JP; Sanabria Á; Tárraga L; Ruíz A; Marquié M; Seo SW; Jang H; Boada M;
    Alzheimers Res Ther; 2023 Jan; 15(1):2. PubMed ID: 36604729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma Amyloid and in vivo Brain Amyloid in Late Middle-Aged Hispanics.
    Rippon B; Palta P; Tahmi M; Sherwood G; Soto L; Cespedes S; Mesen Y; He H; Laing K; Moreno H; Teresi J; Razlighi Q; Brickman AM; Zetterberg H; Luchsinger JA
    J Alzheimers Dis; 2022; 87(3):1229-1238. PubMed ID: 35466933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort.
    Chatterjee P; Pedrini S; Doecke JD; Thota R; Villemagne VL; Doré V; Singh AK; Wang P; Rainey-Smith S; Fowler C; Taddei K; Sohrabi HR; Molloy MP; Ames D; Maruff P; Rowe CC; Masters CL; Martins RN;
    Alzheimers Dement; 2023 Apr; 19(4):1117-1134. PubMed ID: 36574591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional study.
    Boerwinkle AH; Gordon BA; Wisch J; Flores S; Henson RL; Butt OH; McKay N; Chen CD; Benzinger TLS; Fagan AM; Handen BL; Christian BT; Head E; Mapstone M; Rafii MS; O'Bryant S; Lai F; Rosas HD; Lee JH; Silverman W; Brickman AM; Chhatwal JP; Cruchaga C; Perrin RJ; Xiong C; Hassenstab J; McDade E; Bateman RJ; Ances BM; ;
    Lancet Neurol; 2023 Jan; 22(1):55-65. PubMed ID: 36517172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting Amyloid Burden to Accelerate Recruitment of Secondary Prevention Clinical Trials.
    Langford O; Raman R; Sperling RA; Cummings J; Sun CK; Jimenez-Maggiora G; Aisen PS; Donohue MC
    J Prev Alzheimers Dis; 2020; 7(4):213-218. PubMed ID: 32920622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlations between plasma and PET beta-amyloid levels in individuals with subjective cognitive decline: the Fundació ACE Healthy Brain Initiative (FACEHBI).
    de Rojas I; Romero J; Rodríguez-Gomez O; Pesini P; Sanabria A; Pérez-Cordon A; Abdelnour C; Hernández I; Rosende-Roca M; Mauleón A; Vargas L; Alegret M; Espinosa A; Ortega G; Gil S; Guitart M; Gailhajanet A; Santos-Santos MA; Moreno-Grau S; Sotolongo-Grau O; Ruiz S; Montrreal L; Martín E; Pelejà E; Lomeña F; Campos F; Vivas A; Gómez-Chiari M; Tejero MA; Giménez J; Pérez-Grijalba V; Marquié GM; Monté-Rubio G; Valero S; Orellana A; Tárraga L; Sarasa M; Ruiz A; Boada M;
    Alzheimers Res Ther; 2018 Nov; 10(1):119. PubMed ID: 30497535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease.
    Janelidze S; Teunissen CE; Zetterberg H; Allué JA; Sarasa L; Eichenlaub U; Bittner T; Ovod V; Verberk IMW; Toba K; Nakamura A; Bateman RJ; Blennow K; Hansson O
    JAMA Neurol; 2021 Nov; 78(11):1375-1382. PubMed ID: 34542571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma Aβ as a biomarker for predicting Aβ-PET status in Alzheimer's disease：a systematic review with meta-analysis.
    Cheng L; Li W; Chen Y; Lin Y; Wang B; Guo Q; Miao Y
    J Neurol Neurosurg Psychiatry; 2022 May; 93(5):513-520. PubMed ID: 35241627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive Accuracy of Blood-Derived Biomarkers for Amyloid-β Brain Deposition Along with the Alzheimer's Disease Continuum: A Systematic Review.
    Cianflone A; Coppola L; Mirabelli P; Salvatore M
    J Alzheimers Dis; 2021; 84(1):393-407. PubMed ID: 34542072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemically treated plasma Aβ is a potential blood-based biomarker for screening cerebral amyloid deposition.
    Park JC; Han SH; Cho HJ; Byun MS; Yi D; Choe YM; Kang S; Jung ES; Won SJ; Kim EH; Kim YK; Lee DY; Mook-Jung I
    Alzheimers Res Ther; 2017 Mar; 9(1):20. PubMed ID: 28330509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ultrasensitive Detection of Plasma Amyloid-β as a Biomarker for Cognitively Normal Elderly Individuals at Risk of Alzheimer's Disease.
    Chatterjee P; Elmi M; Goozee K; Shah T; Sohrabi HR; Dias CB; Pedrini S; Shen K; Asih PR; Dave P; Taddei K; Vanderstichele H; Zetterberg H; Blennow K; Martins RN
    J Alzheimers Dis; 2019; 71(3):775-783. PubMed ID: 31424403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of gut microbiota and plasma amyloid-β as a potential index for identifying preclinical Alzheimer's disease: a cross-sectional analysis from the SILCODE study.
    Sheng C; Yang K; He B; Du W; Cai Y; Han Y
    Alzheimers Res Ther; 2022 Feb; 14(1):35. PubMed ID: 35164860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Definition of a Threshold for the Plasma Aβ42/Aβ40 Ratio Measured by Single-Molecule Array to Predict the Amyloid Status of Individuals without Dementia.
    Colmant L; Boyer E; Gerard T; Sleegers K; Lhommel R; Ivanoiu A; Lefèvre P; Kienlen-Campard P; Hanseeuw B
    Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Total Aβ
    Doecke JD; Pérez-Grijalba V; Fandos N; Fowler C; Villemagne VL; Masters CL; Pesini P; Sarasa M;
    Neurology; 2020 Apr; 94(15):e1580-e1591. PubMed ID: 32179698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.